A Short Synthesis of Conformationally Constrained Unnatural Bicyclic Amino Acids Containing a Nitrogen Atom at the Ring Juncture: (9aR)- and (9aS)-Octahydropyrido[1,2-a]pyrazine-(3S)-carboxylic Acids (Opc)

Soon Mog So; Chang-Eun Yeom; Seong Mi Cho; Soo Young Choi; Young Keun Chung; B. Moon Kim

doi:10.1055/s-2008-1042762

LETTER

A Short Synthesis of Conformationally Constrained Unnatural Bicyclic Amino Acids Containing a Nitrogen Atom at the Ring Juncture: (9aR)- and (9aS)-Octahydropyrido[1,2-a]pyrazine-(3S)-carboxylic Acids (Opc)

Soon Mog So, Chang-Eun Yeom, Seong Mi Cho, Soo Young Choi, Young Keun Chung, B. Moon Kim*
Department of Chemistry, College of Natural Sciences, Seoul National University, Seoul 151-747, Korea
Fax: +82(2)8727505; e-Mail: kimbm@snu.ac.kr;

Abstract

All articles of this category

Abstract

A short and efficient route to conformationally constrained amino acid analogues, (9aR)- and (9aS)-octahydropyrido[1,2-a]pyrazine-(3S)-carboxylate (Opc) has been developed. The new bicyclic amino acid derivatives can be stored and utilized as a modular unit for the construction of unnatural oligopeptides using conventional peptide coupling methods.

Key words

conformationally constrained - unnatural amino acid - bicyclic - peptidomimetic - cyclic sulfamidate

Full Text

References

References and Notes

For a review, see:

<A NAME="RU12107ST-1A">1a</A> Goodmann M. Ro S. In Burger’s Medicinal Chemistry and Drug Discovery Vol. 1: Wolff ME. John Wiley and Sons; New York: 1995. p.803-861

<A NAME="RU12107ST-1B">1b</A> Gibson SE. Guillo N. Tozer MJ. Tetrahedron 1999, 55: 585

<A NAME="RU12107ST-1C">1c</A> Hruby VJ. Acc. Chem. Res. 2001, 34: 389

For example, see:

<A NAME="RU12107ST-2A">2a</A> Roberts NA. Martin JA. Kinchington D. Broadhurst AV. Craig JC. Duncan IB. Galpin SA. Handa BK. Kay J. Krohn A. Lambert RW. Merrett JH. Mills JS. Parkes KEB. Redshaw S. Ritchie AJ. Taylor DL. Thomas GJ. Machin PJ. Science 1990, 248: 358

<A NAME="RU12107ST-2B">2b</A> Kalish VJ. Tetlock JH. Davies JF. Kaldor SW. Dressman BA. Reich S. Pino M. Nyugen D. Appelt K. Musick L. Wu B. Bioorg. Med. Chem. Lett. 1995, 5: 727

<A NAME="RU12107ST-2C">2c</A> Ghosh AK. Hussain KA. Fidanze S. J. Org. Chem. 1997, 62: 6080

For example, see:

<A NAME="RU12107ST-3A">3a</A> Hunt JT. Lee VG. Leftheris K. Seizinger B. Carboni J. Mabus J. Ricca C. Yan N. Manne V. J. Med. Chem. 1996, 39: 353

<A NAME="RU12107ST-3B">3b</A> Georg GI. Harriman GB. Ali SM. Datta A. Hepperle M. Himes RH. Bioorg. Med. Chem. Lett. 1997, 5: 115

For example, see:

<A NAME="RU12107ST-4A">4a</A> Bigge CF. Wu J. Malone TC. Taylor CP. Vartanian MG. Bioorg. Med. Chem. Lett. 1993, 3: 39

<A NAME="RU12107ST-4B">4b</A> Ho B. Crider AM. Stables JP. Eur.
J. Med. Chem. 2001, 205

For example, see:

<A NAME="RU12107ST-5A">5a</A> Thurieau C. Félétou M. Hennig P. Raimbaud E. Canet E. Fauchère J. J. Med. Chem. 1996, 39: 2095

<A NAME="RU12107ST-5B">5b</A> Mavunkel BJ. Lu Z. Goehring RR. Lu S. Chakravarty S. Perumattam J. Novotny EA. Connolly M. Valentine H. Kyle DJ. J. Med. Chem. 1996, 39: 3169

<A NAME="RU12107ST-6">6</A> For example, see: Shuman RT. Rothenberger RB. Campbell CS. Smith GF. Gifford-Moore DS. Gesellchen PD. J. Med. Chem. 1993, 36: 314

For example, see:

<A NAME="RU12107ST-7A">7a</A> Klutchko S. Blankley CJ. Fleming RW. Hinkley JM. Werner AE. Nordin I. Holmes A. Hoefle ML. Cohen DM. J. Med. Chem. 1986, 29: 1953

<A NAME="RU12107ST-7B">7b</A> Rosenkranz RP. Hayashi CM. Lakatos I. McClelland DL. Proc. West. Pharmacol. Soc. 1989, 32: 221

<A NAME="RU12107ST-8">8</A> For example, see: Steinbaugh BA. Hamilton HW. Patt WC. Rapundalo ST. Batley BA. Lunney EA. Ryan MJ. Hicks GW. Bioorg. Med. Chem. Lett. 1994, 4: 2029

<A NAME="RU12107ST-9">9</A> For example, see: Klutchko S. Hamby JM. Hodges JC. Bioorg. Med. Chem. Lett. 1994, 4: 57

<A NAME="RU12107ST-10A">10a</A> Katritzky AR. Rachwal S. Rachwal B. Tetrahedron 1996, 52: 15031

<A NAME="RU12107ST-10B">10b</A> Barbier D. Marazano C. Riche C. Das BC. Potier P. J. Org. Chem. 1998, 63: 1767

<A NAME="RU12107ST-10C">10c</A> Mash EA. Williams LJ. Pfeiffer SS. Tetrahedron Lett. 1997, 38: 6977

<A NAME="RU12107ST-10D">10d</A> Kametani T. The Total Synthesis of Isoquinoline Alkaloids, In The Total Synthesis of Natural Products Vol. 3: ApSimon J. John Wiley; New York: 1977. p.1-272

<A NAME="RU12107ST-11A">11a</A> Kim BM. Bae SJ. So SM. Yoo HT. Chang SK. Lee JH. Kang JS. Org. Lett. 2001, 3: 2349

<A NAME="RU12107ST-11B">11b</A> Kim BM. Vacca JP. Guare JP. Hanifin CM. Michelson SR. Darke PL. Zugay JA. Emini EA. Schleif W. Lin JH. Chen I.-W. Vastag K. Ostovic D. Anderson PS. Huff JR. Bioorg. Med. Chem. Lett. 1994, 4: 2273

<A NAME="RU12107ST-11C">11c</A> Kim BM. G uare JP. Vacca JP. Michelson SR. Darke PL. Zugay JA. Emini EA. Schleif W. Lin JH. Chen I.-W. Vastag K. Anderson PS. Huff JR. Bioorg. Med. Chem. Lett. 1995, 5: 185

<A NAME="RU12107ST-12A">12a</A> Kim BM, Graham SL, Shaw AW, de Solms J, and Ciccarone T. inventors; US 5,817,678.

<A NAME="RU12107ST-12B">12b</A> Kim BM, Shaw AW, Graham SL, de Solms JS, and Ciccarone TM. inventors; EP 0862435.

<A NAME="RU12107ST-13A">13a</A> Baldwin JE. Spivey AC. Schofield CJ. Tetrahedron: Asymmetry 1990, 1: 881

<A NAME="RU12107ST-13B">13b</A> Ok D. Fisher MH. Wyvratt MJ. Meinke PT. Tetrahedron Lett. 1999, 40: 3831

<A NAME="RU12107ST-13C">13c</A> Cohen SB. Halcomb RL. Org. Lett. 2001, 3: 405

<A NAME="RU12107ST-13D">13d</A> Atfani M. Wei L. Lubell WD. Org. Lett. 2001, 3: 2965

<A NAME="RU12107ST-13E">13e</A> Cohen SB. Halcomb RL. J. Am. Chem. Soc. 2002, 124: 2534

<A NAME="RU12107ST-13F">13f</A> Nicolaou KC. Huang X. Snyder SA. Rao PB. Bella M. Reddy MV. Angew. Chem. Int. Ed. 2002, 41: 834

<A NAME="RU12107ST-13G">13g</A> Posakony JJ. Grierson JR. Tewson TJ. J. Org. Chem. 2002, 67: 5164

<A NAME="RU12107ST-13H">13h</A> Pound MK. Davies DL. Pilkington MPV. Sousa MM. Wallis JD. Tetrahedron Lett. 2002, 43: 1915

<A NAME="RU12107ST-14A">14a</A> Kim BM. So SM. Tetrahedron Lett. 1998, 39: 5381

<A NAME="RU12107ST-14B">14b</A> Kim BM. So SM. Tetrahedron Lett. 1999, 40: 7687

<A NAME="RU12107ST-14C">14c</A> Kim BM. Bae SJ. So SM. Yoo HT. Chang SK. Lee JH. Kang JS. Org. Lett. 2001, 3: 2349

<A NAME="RU12107ST-14D">14d</A> Kim BM. So SM. Choi HJ. Org. Lett. 2002, 4: 949

<A NAME="RU12107ST-15A">15a</A> Baldwin JE. Adlington RM. Mellor LC. Tetrahedron 1994, 50: 5049

<A NAME="RU12107ST-15B">15b</A> Augilera B. Mayoralas AF. Jaramillo C. Tetrahedron 1997, 53: 5863

<A NAME="RU12107ST-15C">15c</A> Wel L. Lubell WD. Org. Lett. 2000, 2: 2595

<A NAME="RU12107ST-16">16</A> Rodwell VW. Methods in Enzymology Part B, Vol. 17: Academic Press; New York: 1971. p.174

<A NAME="RU12107ST-17">17</A> Henry JR. Marcin LR. McIntosh C. Scola PM. Harris GD. Weinreb SM. Tetrahedron Lett. 1989, 30: 5709

<A NAME="RU12107ST-18A">18a</A> Pederson CJ. J. Am. Chem. Soc. 1967, 89: 7017

<A NAME="RU12107ST-18B">18b</A> Alexander V. Chem. Rev. 1995, 95: 273

<A NAME="RU12107ST-19A">19a</A> Sharpless KB. Kim BM. Tetrahedron Lett. 1989, 30: 655

<A NAME="RU12107ST-19B">19b</A> Okada M. Tomioka K. Tetrahedron Lett. 1994, 35: 4585

CCDC #660993.

Characterization Data for Compound 16 [α]_D ²⁷ -15.0 (c 1.1, CHCl₃). ¹H NMR (300 MHz, CDCl₃):
δ = 0.03 (s, 6 H), 0.88 (s, 9 H), 1.28 (t, 3 H), 1.32-1.70 (m, 6 H), 2.23-2.45 (m, 1 H), 2.50-2.57 (m, 1 H), 2.64-2.76 (m, 3 H), 2.97-3.05 (m, 1 H), 3.38-3.51 (m, 2 H), 3.94 (ABq, J = 13.3 Hz, 2 H), 3.96-3.88 (m, 1 H), 4.26-4.32 (m, 2 H), 7.21-7.32 (m, 5 H). ¹³C NMR (75 MHz, CDCl₃): δ = -5.47, 14.28, 18.21, 22.16, 25.39, 25.84, 28.20, 51.06, 52.14, 56.96, 59.58, 60.34, 62.17, 63.70, 126.86, 128.16, 128.22, 139.85, 174.46. HRMS (CI): m/z calcd for C₂₃H₄₁N₂O₃Si
[M + H]⁺: 421.2886; found: 421.2884.

Characterization Data for Compound 17 [α]_D ²⁸ -4.1 (c 1.1, CHCl₃). ¹H NMR (300 MHz, CDCl₃): δ = 1.29 (t, 3 H), 1.37-1.71 (m, 6 H), 2.27-2.45 (m, 2 H), 2.57-2.64 (m, 1 H), 2.82-2.91 (m, 1 H), 2.98-3.05 (m, 1 H), 3.22 (br s, 2 H), 3.35-3.42 (m, 2 H), 3.67-3.76 (m, 1 H), 3.75 (ABq, J = 12.9, 2 H), 4.13-4.24 (m, 2 H), 7.22-7.32 (m, 5 H). ¹³C NMR (75 MHz, CDCl₃): δ = 14.25, 23.71, 23.86, 27.05, 52.47, 52.74, 54.38, 59.89, 60.92, 61.95, 63.07, 127.20, 128.35, 128.42, 139.03, 174.90. HRMS (CI): m/z calcd for C₁₈H₂₉N₂O₃ [M + H]⁺: 321.2178; found: 321.2176.

Characterization Data for Compound 19 [α]_D ²⁷ -10.5 (c 1.0, CHCl₃). ¹H NMR (300 MHz, CDCl₃):
δ = 1.12-1.29 (m, 2 H), 1.27 (t, 3 H), 1.34-1.41 (m, 1 H), 1.56-1.59 (m, 2 H), 1.65-1.68 (m, 1 H), 1.87-1.96 (m, 2 H), 2.38-2.48 (m, 2 H), 2.70-2.74 (m, 1 H), 2.90-2.97 (m, 1 H), 3.04-3.08 (m, 1 H), 3.40 (s, 1 H), 3.90 (ABq, J = 13.7, 2 H), 4.14-4.24 (m, 2 H), 7.20-7.31 (m, 5 H). ¹³C NMR (75 MHz, CDCl₃): δ = 14.78, 24.37, 25.96, 29.91, 53.41, 56.15, 58.27, 59.35, 60.25, 60.62, 61.85, 127.30, 128.65, 129.03, 139.75, 172.83. HRMS (CI): m/z calcd for C₁₈H₂₇N₂O₂ [M + H]⁺: 303.2072; found: 303.2073.

Characterization Data for Compound 22 [α]_D ¹¹ -31.3 (c 1.00, CHCl₃).¹H NMR (300 MHz, CDCl₃):
δ = 1.11-1.96 (m, 17 H), 2.24-2.31 (m, 1 H), 2.70-2.88 (m, 2 H), 3.17-3.24 (m, 1 H), 3.62 (d, J = 3.2 Hz, 0.25 H), 3.66 (d, J = 3.2 Hz, 0.25 H), 3.74-3.80 (m, 3.5 H), 4.53 (d, J = 4 Hz, 0.5 H), 4.70 (d, J = 4 Hz, 0.5 H). ¹³C NMR (75 MHz, CDCl₃): δ = 24.02, 24.07, 25.67, 28.64, 28.73, 29.54, 29.56, 46.87, 47.84, 52.58, 54.38, 55.65, 55.81, 55.93, 56.17, 60.70, 60.72, 80.55, 80.60, 155.54, 155.96, 171.68, 171.98. HRMS-FAB: m/z calcd for C₁₅H₂₇N₂O₄ [M + H]⁺: 299.1971; found: 299.1970.

Characterization Data for Compound 23 [α]_D ¹¹ +23.9 (c 1.00, CHCl₃). ¹H NMR (300 MHz, CDCl₃): δ = 1.12-1.28 (m, 2 H), 1.51-1.61 (m, 3 H), 1.72-1.98 (m, 3 H), 2.03 (s, 0.7 H), 2.14 (s, 2.3 H), 2.24 (dd, 0.75 H), 2.33 (dd, 0.25 H), 2.49-2.61 (m, 0.25 H), 2.77-2.80 (m, 0.75 H), 3.09-3.18 (m, 0.9 H), 3.24-3.38 (m, 1.2 H), 3.43-3.54 (m, 0.9 H), 3.75 (s, 2.3 H), 3.79 (s, 0.7 H), 4.22-4.23 (m, 0.08 H), 4.27-4.28 (m, 0.08 H), 4.34-4.37 (m, 0.14 H), 5.17-5.19 (m, 0.7 H). ¹³C NMR (75 MHz, CDCl₃): δ = 21.52, 21.81, 23.98, 25.58, 25.67, 29.55, 29.62, 45.07, 49.88, 52.51, 52.76, 53.12, 55.72, 55.82, 56.04, 56.43, 57.57, 60.63, 60.98, 170.79, 171.01, 171.22. HRMS-FAB: m/z calcd for C₁₂H₂₁N₂O₃ [M + H]⁺: 241.1552; found: 241.1558.

Characterization Data for Compound 24 [α]_D ¹¹ -59.2 (c 1.00, CHCl₃). ¹H NMR (300 MHz, CDCl₃):
δ = 1.03-1.31 (m, 2 H), 1.41-2.01 (m, 6 H), 2.12 (s, 1.2 H), 2.23 (m, 1.8 H), 2.34-2.52 (m, 2 H), 2.78-2.86 (m, 1 H), 3.03-3.15 (m, 1 H), 3.29-3.33 (m, 0.4 H), 3.44-3.48 (m, 0.4 H), 3.71-3.78 (m, 0.2 H), 4.32-4.55 (m, 2.6 H), 5.18-5.20 (m, 0.4 H), 7.05 (s, 0.4 H), 7.26-7.69 (m, 5 H), 8.46 (m, 0.6 H). ¹³C NMR (75 MHz, CDCl₃): δ = 21.89, 21.96, 23.81, 23.94, 25.62, 25.89, 29.62, 29.74, 43.78, 43.83, 44.07, 50.02, 52.95, 55.26, 55.52, 55.735, 55.89, 57.70, 60.75, 61.26, 126.29, 127.75, 127.88, 127.91, 128.22, 129.050, 129.14, 138.39, 138.70, 169.76, 170.05, 170.51, 170.91. HRMS-FAB: m/z calcd for C₁₈H₂₆N₃O₂ [M + H]⁺: 316.2025; found: 316.2026.